Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.
暂无分享,去创建一个
Richie Soong | Ross A Soo | B. Goh | R. Soong | R. Soo | S. Ng | W. Yong | L. Tham | Jian Jun Liu | S. C. Lee | Soo Chin Lee | Tai Bee Choo | Ling Zhi Wang | Swee Siang Ng | Pei Yi Chong | Wei Peng Yong | Lai San Tham | How Sung Lee | Boon Cher Goh | Lingzhi Wang | How-sung Lee | P. Chong
[1] C. Ulrich,et al. Cancer pharmacogenetics: polymorphisms, pathways and beyond , 2003, Nature Reviews Cancer.
[2] M. Taron,et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] G. Hillerdal,et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F. Cappuzzo,et al. Role of gemcitabine in cancer therapy. , 2005, Future oncology.
[5] H. Ueno,et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Honghao Zhou,et al. Ethnic Differences in Drug Disposition and Responsiveness , 1991, Clinical pharmacokinetics.
[7] W. Gregory,et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[9] H. McLeod,et al. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway , 2004, The Pharmacogenomics Journal.
[10] Joanne Wang,et al. (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters , 2004 .
[11] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[12] K. Naito,et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy , 2006, British Journal of Cancer.
[13] J. Mackey,et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. , 1999, Journal of the National Cancer Institute.
[14] S. Groshen,et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab , 2006, Pharmacogenetics and genomics.
[15] W. Plunkett,et al. Preclinical characteristics of gemcitabine , 1995, Anti-cancer drugs.
[16] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[17] G. Peters,et al. Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. , 1998, Advances in experimental medicine and biology.
[18] L. Bertilsson,et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. , 1996, Pharmacogenetics.
[19] S. Groshen,et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer , 2004, British Journal of Cancer.
[20] Conrad C. Huang,et al. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2 , 2005, Pharmacogenetics and genomics.
[21] B. Goh,et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population , 2006, Clinical pharmacology and therapeutics.
[22] Y Z Xu,et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.
[23] H. Ueno,et al. Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin , 2005, Clinical Cancer Research.
[24] V. Heinemann,et al. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.
[25] Conrad C. Huang,et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. , 2004, Molecular pharmacology.
[26] H. Groen,et al. Genetic factors influencing Pyrimidine-antagonist chemotherapy , 2005, The Pharmacogenomics Journal.
[27] R. Diasio,et al. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. , 2005, Pharmacogenomics.
[28] G. Bepler,et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. , 2005, Lung cancer.
[29] R. Hitt,et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Watanabe,et al. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. , 2003, Cancer research.
[31] Y Z Xu,et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.
[32] Li Wan Po,et al. Pharmacogenetics and psychopharmacotherapy , 2000, Journal of clinical pharmacy and therapeutics.